VRCA
Verrica Pharmaceuticals Inc.
Next earnings Aug 10, 2026 · consensus $-0.40 EPS, $6.10M rev
Last earnings -3.4% on 2026-05-12
$6.84
▲ +10.14%$6.84▲ +16.47%
over 1Y
L $3.28EODHDH $9.10
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+10.1%
1W+21.3%
1M+12.9%
3M+56.2%
YTD-17.6%
1Y+16.5%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 12 analysts
Buy
Revenue grew 370.2% YoY; but unprofitable (net margin -50.3%).
Revenue (FY2025) $35.6M · FY2025
Verrica Pharmaceuticals Inc. shows $35.6M in FY2025 revenue (+370.2% YoY), a -50.3% net margin, and -72.3% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $7.57M | $35.6M |
| Gross profit | — | — | — | — | — |
| Operating income | -$30.9M | -$21.3M | -$65.8M | -$65.9M | -$12.2M |
| Net income | -$35.1M | -$24.5M | -$67.0M | -$76.6M | -$17.9M |
| Diluted EPS | -$1.30 | -$0.72 | -$1.48 | -$14.78 | -$1.68 |
| Net margin | — | — | — | -1012.1% | -50.3% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$87.4M
EV / EBITDA—
EV / Sales2.5
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-15.2%
FCF yield-15.0%
Quality & risk
ROIC (est.)-38.9%
Free cash flow-$17.6M
Total debt$0.00
Net cash$30.1M
Altman Z-Score-5.94 distress
Piotroski F-Score6/8
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY-81.3%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
- 8-K Officer / director change2026-06-09
- 8-K Earnings results2026-05-12
- 10-Q Quarterly report2026-05-12
- DEF 14A Proxy statement2026-04-20
- 8-K Earnings results2026-03-11
- 10-K Annual report2026-03-11
- 8-K Officer / director change2025-12-30
- S-3 Shelf registration (potential raise)2025-12-15
- 8-K Material agreement2025-11-24
Recent filings
all on EDGAR ↗4Period ending 2026-06-052026-06-09open ↗4Period ending 2026-06-052026-06-09open ↗4Period ending 2026-06-052026-06-09open ↗4Period ending 2026-06-052026-06-09open ↗4Period ending 2026-06-052026-06-09open ↗4Period ending 2026-06-052026-06-09open ↗4Period ending 2026-06-052026-06-09open ↗8-KPeriod ending 2026-06-052026-06-09open ↗S-8Filing2026-05-12open ↗10-QPeriod ending 2026-03-312026-05-12open ↗8-KPeriod ending 2026-05-122026-05-12open ↗ARSPeriod ending 2025-12-312026-04-20open ↗
Frequently asked
- Is Verrica Pharmaceuticals Inc. (VRCA) a buy?
- VRCA currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Revenue grew 370.2% YoY; but unprofitable (net margin -50.3%).
- What is Verrica Pharmaceuticals Inc.'s quality score?
- VRCA scores 59.70588235294117/100 (grade C) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001660334, latest 10-Q filed 2026-05-12) · EODHD · as of 6/26/2026, 8:22:07 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.